Zoltie N, Cust M P
Ann R Coll Surg Engl. 1986 Jul;68(4):209-10.
In a prospective sequential double blind trial 288 patients with acute abdominal pain were given sublingual buprenorphine 200 mcg, sublingual buprenorphine 400 mcg, or placebo. Pain relief was proportional to the number of tablets administered; buprenorphine had no difference in effect compared to placebo. Physical signs altered in proportion to dosage, but this had no effect on clinical diagnosis. We conclude that patients with acute abdominal pain may be given buprenorphine without fear of masking the diagnosis.
在一项前瞻性序贯双盲试验中,288例急性腹痛患者分别接受200微克舌下丁丙诺啡、400微克舌下丁丙诺啡或安慰剂治疗。疼痛缓解程度与给药片数成正比;丁丙诺啡与安慰剂相比效果无差异。体征变化与剂量成正比,但这对临床诊断没有影响。我们得出结论,急性腹痛患者可以使用丁丙诺啡,而不必担心掩盖诊断。